NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE: ARE) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Alexandria Real Estate, you are encouraged to obtain additional information by visiting: https://w ...

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. and certain senior executives for securities fraud following significant stock drops due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - Investors have until March 13, 2026, to request to be appointed to lead the case, which is based on claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2][3]. - The lawsuit is pending in the U.S. District Court for the Southern District of Ohio, captioned Lingam v. Bath & Body Works, Inc., et al., No. 2:26-cv-00039 [3]. Group 2: Company Performance and Strategy - Bath & Body Works is a specialty retailer focusing on home fragrance and body care products, exploring product categories beyond its core business, including men's products, lip care, hair care, and laundry items [4]. - The company claimed that customers were responding favorably to its innovations and that its strategy was driving topline growth through these new categories [5]. Group 3: Stock Performance - On August 28, 2025, Bath & Body Works reported disappointing Q2 2025 financial results, cutting its full-year earnings guidance by $0.03 to a range of $3.28 to $3.53 per diluted share, leading to a stock price drop of $2.18, or 6.9%, from $31.54 to $29.36 per share [6]. - Following the release of Q3 2025 financial results on November 20, 2025, which included a further reduction in full-year guidance and acknowledgment that the strategy had not grown the customer base, the stock fell by $5.22, or 24.8%, from $21.04 to $15.82 per share [7].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Ohio, captioned Lingam v. Bath & Body Works, Inc., et al., No. 2:26-cv-00039 [3]. - Investors have until March 13, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Strategy - Bath & Body Works is a specialty retailer focusing on home fragrance and body care products, exploring product categories beyond its core business, including men's products, lip care, hair care, and laundry items [4]. - The company claimed that customers were responding favorably to its innovations and that its strategy was driving topline growth through category adjacencies [5]. Group 3: Stock Performance - On August 28, 2025, Bath & Body Works reported disappointing Q2 2025 results, cutting its full-year earnings guidance by $0.03 to a range of $3.28 to $3.53, leading to a stock drop of $2.18 per share, or 6.9% [6]. - Following the Q3 2025 results on November 20, 2025, which revealed that the strategy of pursuing adjacencies had not grown the customer base, the stock fell by $5.22 per share, or 24.8% [7].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements that negatively impacted investors [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Bath & Body Works securities between June 4, 2024, and November 19, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against the Company - The complaint alleges that Bath & Body Works made false and misleading statements regarding its business strategy, which included seeking "adjacencies, collaborations and promotions" that failed to grow its customer base and net sales [4]. - The company reportedly relied on brand collaborations to "carry quarters" despite experiencing weak financial results, leading to misleading public statements throughout the class period [4]. - Investors suffered damages when the truth about the company's performance was revealed [4].

Core Points - A class action lawsuit has been filed against CoreWeave, Inc. for violations of the Securities Exchange Act of 1934 [1] - The lawsuit pertains to investors who purchased CoreWeave's securities between March 28, 2025, and December 15, 2025 [2] - The complaint alleges that CoreWeave made false and misleading statements regarding its ability to meet customer demand and downplayed risks associated with relying on a single third-party vendor for data centers [4] Company Operations - CoreWeave's failed acquisition of Core Scientific and delays in bringing data centers online contributed to the misleading public statements [4] - The truth about CoreWeave's operations was revealed through media reporting, leading to investor damages when the market learned the facts [4] Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits [5] - Investors are encouraged to contact the firm to discuss their rights and potential participation in the lawsuit [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Galectin Therapeutics Inc. and its officers or directors [1] Group 1: Company Developments - On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, an investigational galectin-3 inhibitor [3] - The FDA's response converted the initial request for an in-person or teleconference meeting to a written format, indicating that key aspects of the trial design remain unresolved despite alignment on the proposed patient population for a registration trial [3] Group 2: Market Reaction - Following the news of the FDA's response, Galectin's stock price fell by $1.78 per share, or 28.9%, closing at $4.38 per share on December 19, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving BigBear.ai Holdings, Inc. and its officers or directors [1] Group 1: Company Performance - Cantor analysts downgraded BigBear from Overweight to Neutral on January 7, 2026, citing a 20% year-over-year revenue decline [3] - The company reported an adjusted EBITDA of ($9.4 million) in Q3 2025 and an operating margin of (66.0%) [3] - Following the downgrade, BigBear's stock price decreased by $0.42 per share, or 6.55%, closing at $5.99 per share on January 7, 2026 [3] Group 2: Legal Investigation - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [1]

Core Viewpoint - Sigma Lithium Corporation is under investigation for potential securities fraud and unlawful business practices, following a downgrade by Bank of America due to unresolved operational and liquidity issues [1][3]. Group 1: Investigation and Legal Actions - Pomerantz LLP is investigating claims on behalf of Sigma Lithium investors regarding possible securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the class action [2]. Group 2: Stock Performance and Analyst Downgrade - On January 8, 2026, Bank of America downgraded Sigma Lithium from Neutral to Underperform, citing unresolved operational and liquidity issues [3]. - Following the downgrade, Sigma Lithium's stock price decreased by $2.36 per share, or 15.07%, closing at $13.30 per share on the same day [3].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drops linked to alleged violations of federal securities laws [1][3]. Company Overview - Fermi Inc. is an energy and AI infrastructure company focused on building large-scale nuclear reactors to support grid-independent data centers for AI workloads [4]. - The company's flagship project is Project Matador, designed to provide dedicated power for AI operations [4]. IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Stock Price Impact - On December 12, 2025, Fermi's stock dropped by $5.16 per share, over 33%, following the announcement that the First Tenant was terminating the construction funding agreement [7].

Core Viewpoint - A class action lawsuit has been filed against agilon health, inc. for securities fraud, following a significant drop in stock price after the announcement of leadership changes and missed financial estimates [1][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who purchased agilon securities between February 26, 2025, and August 4, 2025, with a deadline of March 2, 2026, for filing a lead plaintiff motion [1]. - The lawsuit alleges that agilon's management made materially false and misleading statements regarding the company's business and financial outlook during the class period [4]. Group 2: Financial Impact - On August 4, 2025, agilon announced the departure of its President, CEO, and Director, which was classified as a termination without cause, leading to a suspension of its 2025 guidance [3]. - Following this announcement, agilon's stock price plummeted by $0.93, or 51.5%, closing at $0.88 per share on August 5, 2025, resulting in significant losses for investors [3]. Group 3: Allegations Against Management - The complaint claims that management recklessly issued guidance for 2025, despite being aware of material industry challenges that would prevent achieving those targets [4]. - It is alleged that management overstated the financial benefits from strategic actions taken to mitigate risks, rendering their positive statements about the company's prospects misleading [4].